Tech Center 1600 • Art Units: 1611 1614 1621 1627 1629
This examiner grants 41% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18207728 | METHODS OF ADMINISTERING GAMMA-HYDROXYBUTYRATE COMPOSITIONS WITH DIVALPROEX SODIUM | Final Rejection | Flamel Ireland Limited |
| 18276929 | CORONAL PROTEIN-COATED NANOPARTICLES AND USES THEREOF | Non-Final OA | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. |
| 18572054 | SUSTAINED RELEASE FORMULATIONS COMPRISING A SELECTIVE ANDROGEN RECEPTOR MODULATOR | Non-Final OA | University of Iowa Research Foundation |
| 18024679 | COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING BRAIN DAMAGE AND MILD COGNITIVE IMPAIRMENT COMPRISING GLUTAMINE AS EFFECTIVE COMPONENT | Final Rejection | INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY |
| 18700760 | ANTIMICROBIAL COMPOSITION AND METHOD FOR MAKING THE SAME | Non-Final OA | WACKER CHEMIE AG |
| 18648420 | ISO-OSMOTIC AND NEAR ISO-OSMOTIC OXYGEN THERAPEUTIC FORMULATIONS AND METHODS THEREOF | Non-Final OA | NuvOx Pharma LLC |
| 18321965 | COMPOSITION FOR PREVENTING OR TREATING BREAST CANCER COMPRISING COMPOUND DERIVED FROM DENDROPANAX MORBIFERUS | Non-Final OA | JEJU NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18105134 | METHOD FOR PRODUCING AN, IN PARTICULAR ORAL, ACTIVE SUBSTANCE LAMINATE, AND ACTIVE SUBSTANCE LAMINATE, IN PARTICULAR ORAL ACTIVE SUBSTANCE LAMINATE | Non-Final OA | LTS LOHMANN THERAPIE-SYSTEME AG |
| 18581843 | EXTRACELLULAR VESICLES FOR THERAPY | Non-Final OA | Leksum LLC |
| 18578902 | COSMETIC COMPOSITION COMPRISING MOLECULAR AGGREGATES OF BILE ACIDS OR BILE ACID SALTS | Non-Final OA | SCAI THERAPEUTICS CO., LTD. |
| 17215677 | FEED MITIGANT COMPOSITIONS FOR INACTIVATING SWINE VIRUSES AND RELATED METHODS | Non-Final OA | Ralco Nutrition, Inc. |
| 18565956 | LACTOBACILLUS PLANTARUM-DERIVED VESICLE AND USE THEREOF | Non-Final OA | MD HEALTHCARE INC. |
| 18289726 | NASAL SLEEP FORMULATION | Non-Final OA | CS MEDICA A/S |
| 18558581 | COPPER NANOCLUSTERS, METHODS FOR OBTAINING SAME AND THE USE THEREOF IN THE TREATMENT OF MENKES DISEASE | Non-Final OA | CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE NANCY (CHRU) |
| 17769398 | CONTROLLED RELEASE FORMULATIONS OF HIGHLY LIPOPHILIC PHYSIOLOGICALLY ACTIVE SUBSTANCES | Final Rejection | ADD Advanced Drug Delivery Technologies Ltd. |
| 16935005 | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Non-Final OA | GW Research Limited |
| 17269106 | METHODS OF TREATING ACUTE STRESS DISORDER AND POSTTRAUMATIC STRESS DISORDER | Non-Final OA | Tonix Pharma Limited |
| 17779722 | USE OF MASITINIB FOR THE TREATMENT OF EOSINOPHILIC ASTHMA | Final Rejection | AB SCIENCE |
| 17346902 | Methods Of Providing Weight Loss Therapy In Patients With Major Depression | Final Rejection | Nalpropion Pharmaceuticals LLC |
| 18044196 | HETEROCYCLIC GLP-1 AGONISTS | Non-Final OA | Gasherbrum Bio, Inc. |
| 18006440 | APPLICATION OF BENFLUMETOL AND DERIVATIVES THEREOF IN TREATMENT OF CORONAVIRUS INFECTION | Non-Final OA | ACADEMY OF MILITARY MEDICAL SCIENCES |
| 18011198 | APPLICATION OF COMPOUND USING INTRA-CYCLIC PEROXO-BRIDGED SESQUITERPENES AS PARENT NUCLEUS IN METABOLISM-RELATED FATTY LIVER DISEASES | Final Rejection | SUZHOU TANGJI BIOTECHNOLOGY CO., LTD. |
| 17282508 | DASATINIB AND ANOTHER 5-THIAZOLECARBOXAMIDE KINASE INHIBITOR, AND USES THEREOF | Final Rejection | iOmx Therapeutics AG |
| 17775230 | TREATMENT OF AUTOINFLAMMATORY DISORDERS | Final Rejection | Inflazome Limited |
| 17753654 | METHOD FOR PREVENTING PRECIPITATION OF INJECTABLE SOLUTION CONTAINING p-BORONOPHENYLALANINE | Non-Final OA | Stella Pharma Corporation |
| 17291169 | PHARMACEUTICAL COMPOSITION WHICH COMPRISES THE COMBINATION OF A SELECTIVE INHIBITOR OF CYCLOOXYGENASE 2 AND A CARBAMATE DERIVED FROM GUAIFENESIN FOR TREATING PAIN, INFLAMMATION AND MUSCULAR CONTRACTION | Final Rejection | Carlos Amezcua Amezcua |
| 17595766 | INTRANASAL ADMINISTRATION OF KETAMINE TO CLUSTER HEADACHE PATIENTS | Non-Final OA | Afyx Development A/S |
| 17434262 | MACROCYCLIC LACTONE ANTHELMINTICS AGAINST NEMATODES | Non-Final OA | Bayer Animal Health GmbH |
| 17402807 | CHEMICAL COMPOSITIONS AND METHODS FOR ENHANCING TRANSDERMAL DELIVERY OF THERAPEUTIC AGENTS | Non-Final OA | InteguRx Therapeutics, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy